Evommune pivots EVO756 away from CSU after Phase 2b trial failure
Evommune disclosed that its Phase 2b trial of EVO756 failed to meet the primary endpoint for chronic spontaneous urticaria. The company will discontinue development in this indication but will use its cash runway to advance the candidate in atopic dermatitis and migraine.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day